Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (281-290 of 448) with videos related to

Pageof 45
Sort By:
The Journal of Rheumatology|September 19, 2006
IL13RA2 gene polymorphisms are associated with systemic sclerosisBrigitte Granel, Yannick Allanore, Christophe Chevillard, et al.
Arthritis and Rheumatism|May 7, 2011
Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observationsChristophe Meune, Jérôme Avouac, Paolo Airò, et al.
Arthritis and Rheumatism|December 6, 2011
Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosisJérôme Avouac, Katrin Palumbo, Michal Tomcik, et al.
Arthritis Research & Therapy|October 29, 2020
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR databaseYannick Allanore, Sylvie Bozzi, Augustin Terlinden, et al.
Clinical and Experimental Rheumatology|August 17, 2024
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationaleDinesh Khanna, Christopher P Denton, Shervin Assassi, et al.
The Lancet. Rheumatology|January 27, 2024
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort studyRucsandra Dobrota, Suzana Jordan, Pernille Juhl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 7, 2022
Driving Role of Interleukin-2-Related Regulatory CD4+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic SclerosisCamelia Frantz, Anne Cauvet, Aurélie Durand, et al.
Chest|October 16, 2022
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and ResearchAnna-Maria Hoffmann-Vold, Cathrine Brunborg, Paolo Airò, et al.
Rheumatology (Oxford, England)|April 9, 2026
18F-fluorodeoxyglucose PET/CT uptake characteristics in ICI-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumaticaArthur Bouchut, Thibaut Jacquet, Yasmine Gouyette, et al.
Immunogenetics|July 13, 2006
Evaluation of interleukin 13 polymorphisms in systemic sclerosisBrigitte Granel, Christophe Chevillard, Yannick Allanore, et al.
Pageof 45

Showing results (281-290 of 448) with videos related to

Sort By:
Pageof 45
The Journal of Rheumatology|September 19, 2006
IL13RA2 gene polymorphisms are associated with systemic sclerosisBrigitte Granel, Yannick Allanore, Christophe Chevillard, et al.
Arthritis and Rheumatism|May 7, 2011
Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observationsChristophe Meune, Jérôme Avouac, Paolo Airò, et al.
Arthritis and Rheumatism|December 6, 2011
Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosisJérôme Avouac, Katrin Palumbo, Michal Tomcik, et al.
Arthritis Research & Therapy|October 29, 2020
Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR databaseYannick Allanore, Sylvie Bozzi, Augustin Terlinden, et al.
Clinical and Experimental Rheumatology|August 17, 2024
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationaleDinesh Khanna, Christopher P Denton, Shervin Assassi, et al.
The Lancet. Rheumatology|January 27, 2024
Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort studyRucsandra Dobrota, Suzana Jordan, Pernille Juhl, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 7, 2022
Driving Role of Interleukin-2-Related Regulatory CD4+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic SclerosisCamelia Frantz, Anne Cauvet, Aurélie Durand, et al.
Chest|October 16, 2022
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and ResearchAnna-Maria Hoffmann-Vold, Cathrine Brunborg, Paolo Airò, et al.
Rheumatology (Oxford, England)|April 9, 2026
18F-fluorodeoxyglucose PET/CT uptake characteristics in ICI-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumaticaArthur Bouchut, Thibaut Jacquet, Yasmine Gouyette, et al.
Immunogenetics|July 13, 2006
Evaluation of interleukin 13 polymorphisms in systemic sclerosisBrigitte Granel, Christophe Chevillard, Yannick Allanore, et al.
Pageof 45